Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases patients' risk for many kinds of cancer.


Speaker 3: (00:32)
Could you provide our listeners with a little bit about yourself and your background?

 

Speaker 3: (01:27)
 Could you give an overview of our MLH1 hypermethylation, also referred to as MLHPB in our test catalog? 

 

Speaker 3: (02:48)
 Can you talk about why your team thought it was really important to develop this test?

 

Speaker 3: (04:03)
 What patients would this testing really benefit?

 

Speaker 3: (06:10)

How are the results used in patient care?

 

Speaker 3: (07:56)
 Anything else you would like our listeners to hear about MLHPB?